Skip to main content

01.12.2019 | Technical innovations | Ausgabe 1/2019 Open Access

World Journal of Surgical Oncology 1/2019

Ultrasound-guided totally implantable venous access ports via the right innominate vein: a new approach for patients with breast cancer

World Journal of Surgical Oncology > Ausgabe 1/2019
Liang Xu, Wenming Qin, Weiwei Zheng, Xingwei Sun
Wichtige Hinweise
Liang Xu and Wenming Qin contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



To evaluate the feasibility and safety of ultrasound-guided totally implantable venous access port (TIVAP) implantation via the right innominate vein in patients with breast cancer.


Sixty-seven breast cancer patients underwent ultrasound-guided implantation of TIVAPs via the right innominate vein for administration of chemotherapy. Clinical data including technical success, success rate for the first attempt, periprocedural, and postoperative complications were recorded and retrospectively studied.


All patients underwent successful surgery. The success rate of the first attempt was 95.52% (64/67). The operation time was 28 to 45 min, with an average of 36 ± 6 min. Periprocedural complications included artery punctures in 1 (1.50%, 1/67) patient. Prior to this study, the mean TIVAP time was 257 ± 3 days (range 41 to 705 days). The rate of postoperative complications was 4.48% (3/67), including catheter-related infections in 1 case and fibrin sheath formation in 2 cases. Up to the present study, three people had unplanned port withdrawal due to complications, and the TIVAPs for 25 patients were still in normal use.


The success rate of ultrasound-guided TIVAPs via the right innominate vein is high with low complications, thus safe and feasible. This technique can provide a new option for chemotherapy of breast cancer patients.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2019

World Journal of Surgical Oncology 1/2019 Zur Ausgabe

Neu im Fachgebiet Chirurgie

06.05.2021 | DDG-Tagung 2021 | Kongressbericht | Nachrichten

Vor- und Nachteile: Welche Geräte lohnen sich?

28.04.2021 | Wechselwirkungen der Krebstherapie | Interview | Ausgabe 5/2021

Sicher therapieren trotz komplexer Medikation

Interview mit Prof. Dr. Ulrich Jaehde, Leiter der Abteilung Klinische Pharmazie am Pharmazeutischen Institut der Rheinischen Friedrich-Wilhelms-Universität Bonn

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.